How do you decide between carboplatin vs not recommending adjuvant chemotherapy entirely for patients with resected NSCLC with relative or absolute contraindications to cisplatin?
ie renal dysfunction, hearing loss, neuropathy
Answer from: Medical Oncologist at Academic Institution
While I am unaware of any study directly addressing this question (in the adjuvant setting), there is clearly a general preference for cisplatin in the curative setting, hence the question. Reworded - is carboplatin SO inferior to cisplatin that you wouldn't give four cycles of a carboplatin r...
Sign in or Register to read more